Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of FLUVIRIN Surface Antigen Inactivated Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
2005-000659-14Phase 2Completed
- Sponsor
- Chiron Vaccines
- Start
- Apr 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated) in influenza (2 arms), sponsored by Chiron Vaccines. Primary endpoints: Immunogenicity (HI antibody response at 21 days) and Safety of single IM injection of FLUVIRIN. Started Apr 2005; status: completed.
02
Drugs
influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on 2005-000659-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000659-14.